At any age: Key facts about pediatric MS

Multiple sclerosis (MS) is a chronic disorder of the central nervous system that disrupts the normal functioning of the brain, optic nerves and spinal cord through inflammation and tissue loss.¹

~2.3 MILLION **12–18 YEARS** Pediatric MS is most commonly people worldwide are affected by diagnosed during adolescence.4 MS, of which 3-5% are estimated to be children.^{2,3} Approximately 98% Compared to adults, children and adolescents have more active of people with 98% pediatric MS have disease with two-to-three times as many relapses.6 relapsing-remitting MS (RRMS).4

RRMS is the form of the disease characterized by **attacks (relapses)** with worsening symptoms, followed by periods of remission where patients can partially or fully recover.⁵

Those with pediatric MS progress to secondary-progressive MS, a highly disabling form of MS, on average **10 years earlier** than those diagnosed as adults.⁴

Pediatric MS affects:

20

Mobility, balance and co-ordination leading to muscle weakness, walking difficulties and tremors.²




Sensation, causing numbness, tingling, dizziness and visual problems.²



Cognitive function (e.g. memory), with **30%** of patients experiencing **significant cognitive impairment**, which can affect attention, performance at school, and relationships with family and friends.^{7,8}







The debilitating symptoms of pediatric MS limit patients' ability to go about everyday activities, like going to school.⁹

The consequences of MS seriously affect academic performance in **over a third** of children.⁸

Symptoms can be difficult for children and adolescents to come to terms with, often causing aggression, depression and anxiety; **50% of patients show signs of depression** within the first two years of disease onset.^{9,10}



Pediatric MS **affects the whole family**, including family interactions and dynamic, as everyone learns how to live with this chronic disease.⁹



Currently, there are **no specifically approved disease-modifying therapies for pediatric MS**; currently used treatments have been **evaluated in direct comparison trials** specifically designed for children and adolescents.¹¹

New treatments are **urgently needed** to improve the lives and long-term outlook of children and adolescents with MS.

References

- PubMed Heath. Multiple Sclerosis (MS). https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0024311. Accessed October 2017.
- 2. Patel Y et al. Pediatric multiple sclerosis. Ann Indian Acad Neurol. 2009;12(4):238-245.
- Multiple sclerosis international federation. Atlas of MS 2013. https://www.msif.org/wp-content/uploads/2014/09/ Atlas-of-MS.pdf. Accessed October 2017.
- 4. Waldman A et al. Pediatric multiple sclerosis. Neurology. 2016;87(9):S74-S81.
- MS Society. Relapsing Remitting (RRMS). http://www.mssociety.org.uk/what-is-ms/types-of-ms/ relapsing-remitting-rrms. Accessed October 2017.
- Gorman MP et al. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol. 2009;66:54-59.

Amato MP et al. Cognitive and psychosocial features of childhood and juvenile MS. Neurology. 2008;70:1891-1897.

- MacAllister WS et al. Cognitive functioning in children and adolescents with multiple sclerosis. Neurology. 2005;64:1422-1425.
- MS Society UK. MS in children. https://www.mssociety.org.uk/ what-is-ms/types-of-ms/ms-in-children. Accessed October 2017.
- 10. Bigi S and Banwell B. Pediatric multiple sclerosis. J Child Neurol. 2012;27(11):1378-1383. Epub 2012 Aug 21.
- International MS Federation. Pediatric MS and other demyelinating disorders in childhood. Current understanding, diagnosis and management. https://www.msif.org/wp-content/ uploads/2016/08/Pediatric-MS-and-other-demyelinatingdisorders-in-childhood-English.pdf. Accessed October 2017.

U NOVARTIS